Elevated soluble ST2 concentration may involve in the progression of atrial fibrillation.

BACKGROUND: The aim of this study is to investigate the value of soluble suppression of tumorigenicity 2 (sST2) in Atrial fibrillation (AF) patients' risk prediction. METHODS: Healthy people (n = 60) and AF patients (n = 194) were consecutively enrolled into this project. RESULTS: In the health group, the mean age was 54 y (55% males). Serum median concentration of sST2 in healthy individuals was 17.04 ng/ml. In the AF patients group, the mean age was 61 years, and 64% were males. Median sST2 value was 21.69 ng/ml. According to subgroup analysis, median sST2 value of paroxysmal and persistent AF patients was 19.82 ng/ml and 24.15 ng/ml, respectively. Emergency AF patients showed much higher median sST2 concentration than AF outpatients (41.59 ng/ml vs. 20.53 ng/ml, p < 0.01). By multiple linear regression analysis adjusted for age and sex, heart failure (HF) and BNP strongly associated with sST2 concentration. After healthy people and AF patients with HF excluded, whether emergency visit or not become a patent predictor of sST2 concentration (n = 172). CONCLUSION: sST2 is probably an objective biomarker that can predict AF patients' risk of emergency admission or HF. Elevated sST2 concentration may involve in the progression of AF.

Expression of matrix metalloproteinase-1 mRNA in peripheral blood mononuclear cells of systemic lupus erythematosus patients and its relationship with atherosclerosis.

BACKGROUND: Matrix metalloproteinase-1 (MMP-1) plays an important role in atherosclerosis. This study was to examine expression of MMP-1 mRNA in peripheral blood mononuclear cells (PBMCs) of patients with systemic lupus erythematosus (SLE), and to explore its relationship with atherosclerosis in SLE. METHODS: Fluorescent quantitative reverse transcription polymerase chain reaction (RT-PCR) was used to examine the expression of MMP-1 mRNA in PBMCs in 80 SLE patients, including 39 prone to atherosclerosis (Group A) and 41 unprone to atherosclerosis (Group B). Meanwhile, 30 patients who were free of cardiovascular diseases and 30 healthy individuals were selected as disease and normal control group (Groups C and D). The changes of MMP-1 gene expression were analyzed by differences of cycle threshold (DeltaCt), with the following formula: DeltaCt = Ct(target) gene - Ct(reference) gene. RESULTS: The expression level of MMP-1 mRNA in Group A was significantly higher than that of group B (DeltaCt = 8.64 +/- 2.43 vs DeltaCt = 12.09 +/- 2.26, t = 6.588, P < 0.01). The expression level of MMP-1 mRNA of SLE patients was significantly higher than that of Group C (DeltaCt = 10.41 +/- 2.90 vs DeltaCt = 12.29 +/- 2.51, t = 3.135, P < 0.01) and Group D (DeltaCt = 10.41 +/- 2.90 vs DeltaCt = 12.48 +/- 1.69, t = 3.675, P < 0.01). CONCLUSIONS: In comparison to disease and control group, expression of MMP-1 mRNA in PBMCs of SLE patients was significantly elevated, and significant difference of MMP-1 mRNA expression was also found between SLE patients prone and unprone to atherosclerosis, indicating that expression of MMP-1 mRNA may be correlated with the pathogenesis and activity of atherosclerosis in SLE.